Article
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
Journal of cancer research and clinical oncology - 1 Jun 2013
Modest D P, Camaj P, Heinemann V, Schwarz B, Jung A, Laubender R P, Gamba S, Haertl C, Stintzing S, Primo S, Bruns C J
Abstract excerpt
PURPOSE: To investigate the impact of different KRAS mutations on treatment with the tyrosine kinase inhibitor sunitinib in SW48 colorectal cancer cell line variants. MATERIALS AND METHODS: Isogenic SW48 KRAS wt, G12A, G12C, G12D, G12R, G12S, G12 V, and G13D cells were evaluated for ERK phosphorylation with and without EGF stimulation. In addition, the respective cell lines were tested for the effect of sunitinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.